Judge dismisses part of J&J claim against Red Cross

Share this article:

A federal judge has dismissed part of the lawsuit brought by Johnson & Johnson against the American Red Cross seeking to restrict the relief organization's use of its iconic logo on first aid, health, safety and emergency preparedness products.

United States District Court for the Southern District of New York Judge Jed Rakoff granted a request by the American Red Cross to dismiss J&J's claim that the relief group  promised not to engage in the sale of first aid, safety and emergency preparedness products, the Red Cross said.

The judge's ruling means that J&J cannot refile arguments on this claim.

Rakoff's order comes nearly three months after J&J first filed suit against the Red Cross.

The court has set a schedule for hearing remaining claims in the case early next year, the Red Cross said.

Rakoff, however, denied a request by the Red Cross and other defendants to throw out certain other breach-of-contract and interference claims brought by the drug maker.

J&J said it was pleased with the decision in a published report.

"It clears the way for Johnson & Johnson to proceed with seven of the eight claims that were originally alleged," Marc Monseau, a J&J spokesman told the Associated Press.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...